8 assets in Endometrial Mixed Adenocarcinoma

Therapeutic assets addressing Endometrial Mixed Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cediranib Endometrial Mixed Adenocarcinoma	National Cancer Institute (NCI)	P2	B (61)
Capivasertib Endometrial Mixed Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Durvalumab Endometrial Mixed Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Endometrial Mixed Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Endometrial Mixed Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Olaparib Endometrial Mixed Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Atezolizumab Endometrial Mixed Adenocarcinoma	UNC Lineberger Comprehensive Cancer Center	P1	CC (43)
Dordaviprone Endometrial Mixed Adenocarcinoma	UNC Lineberger Comprehensive Cancer Center	P1	C (39)